



SUPPLEMENTARY INFORMATION

Supplementary Figure 1




Suppl Figure 1. The HELA cells were treated with overexpression (OE) AAV2-Ctrl and AAV2-Pou2f2 for 2 days, followed by AAV-shRNA-Ctrl and AAV-shPou2f2 for another 2days. This figure demonstrates the efficiency of AAV-mediated Pou2f2 overexpression and deletion and validates the specificity of the Pou2f2 antibody.

Supplementary Figure 2




Suppl Figure 2. The original blots for Figure 2C and 2D. RBPMS, GAPDH antibodies are well-established and Pou2f2 antibody was validated at Suppl Figure 1.

Supplementary Figure 3



Suppl Figure 3. The original blots for Figure 4F. The red dash rectangle indicates the represent blot showing in the manuscript. The HEK cells were treated with overexpression (OE) AAV2-Ctrl and AAV2-Pou2f2 for 3 days. p-S6, GAPDH antibodies are well-established and Pou2f2 antibody was validated at Suppl Figure 1.

Supplementary Figure 4



Suppl Figure 4. The original blots for Figure 4G. The HEK cells were treated with AAV2-Ctrl and AAV2-Pou2f2 for 3 days. pAKT and total AKT were probed at the same blot. p-AKT, AKT, and GAPDH antibodies are well-established.